Sotera Health Reports 9.1% Revenue Growth to $311.3 Million in Q3 2025

Sotera Health Company reported a significant increase in its financial performance for the third quarter of 2025, with total net revenues reaching $311.3 million, a 9.1% increase from $285.5 million in the same period last year. The company's net income surged to $48.4 million, compared to $17.0 million in the prior year, reflecting a 184.7% increase. For the nine months ending September 30, 2025, Sotera Health's revenues totaled $860.2 million, up 6.2% from $810.2 million in 2024, while net income for the same period rose to $43.1 million from $32.1 million.

The growth in revenue was driven by a 7.0% increase in service revenues, which amounted to $255.5 million, and a 19.5% rise in product revenues, totaling $55.8 million. The Sterigenics segment, which provides sterilization services, contributed significantly to this growth, with revenues increasing by 9.8% to $192.8 million. The Nordion segment, focused on Co-60 supply, also saw a notable increase of 22.4% in revenues, reaching $62.8 million. However, the Nelson Labs segment experienced a decline in revenues, dropping 5.0% to $55.7 million, primarily due to decreased expert advisory services.

Operationally, Sotera Health has made strategic moves, including the settlement of litigation related to ethylene oxide (EO) claims, which resulted in a $64.9 million expense for the nine months ended September 30, 2025. The company also reported a decrease in amortization of intangible assets, which fell to $3.1 million for the third quarter, down from $19.9 million a year earlier, as certain intangible assets became fully amortized. The company’s total assets increased to $3.2 billion, up from $3.1 billion at the end of 2024, with cash and cash equivalents rising to $299.2 million.

Looking ahead, Sotera Health remains focused on its growth strategy, which includes potential acquisitions and investments in expanding its facilities. The company has indicated that it expects to continue generating positive cash flows from operations, which will support its capital expenditures and debt servicing needs. As of September 30, 2025, Sotera Health had $2.1 billion in long-term debt, reflecting a decrease from $2.2 billion at the end of 2024, and it has taken steps to manage its interest rate risk through derivative instruments. The company’s outlook remains cautiously optimistic, with plans to navigate ongoing market challenges while capitalizing on growth opportunities in the healthcare sterilization and lab services sectors.